Triple-negative breast cancer (TNBC), characterized by the loss of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2), is the most aggressive subtype, with early recurrence and unfavorable prognosis (Guo et al., 2023; Lee, 2023). Here, PGR is linked to triple-negative breast carcinoma.